Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022
21 oct. 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Moderna exercises option to license proprietary targeting technology from Autolus
12 oct. 2022 07h00 HE
|
Autolus Therapeutics plc
- Option exercised on undisclosed immune-oncology target following evaluation period by Moderna - - Autolus receives option exercise fee, with potential for development milestone payments plus...
Autolus Therapeutics Reports Second Quarter 2022 Financial Results and Operational Progress
04 août 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
21 juil. 2022 07h54 HE
|
Autolus Therapeutics plc
In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version LONDON,...
Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
21 juil. 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress
10 juin 2022 03h01 HE
|
Autolus Therapeutics plc
- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma- AUTO1/22 demonstrates encouraging and durable responses in children ineligible for...
Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022
31 mai 2022 16h01 HE
|
Autolus Therapeutics plc
LONDON, May 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted...
Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress
12 mai 2022 10h51 HE
|
Autolus Therapeutics plc
- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia-...
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL
25 avr. 2022 07h01 HE
|
Autolus Therapeutics plc
LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
31 mars 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...